337 related articles for article (PubMed ID: 30802699)
1. Moving pharmacoepigenetics tools for depression toward clinical use.
Hack LM; Fries GR; Eyre HA; Bousman CA; Singh AB; Quevedo J; John VP; Baune BT; Dunlop BW
J Affect Disord; 2019 Apr; 249():336-346. PubMed ID: 30802699
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoepigenetics: an element of personalized therapy?
Majchrzak-Celińska A; Baer-Dubowska W
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):387-398. PubMed ID: 27860490
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response.
Domschke K; Tidow N; Schwarte K; Ziegler C; Lesch KP; Deckert J; Arolt V; Zwanzger P; Baune BT
J Neural Transm (Vienna); 2015 Jan; 122(1):99-108. PubMed ID: 24809685
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic and epigenomic biomarkers of antidepressant response.
Belzeaux R; Lin R; Ju C; Chay MA; Fiori LM; Lutz PE; Turecki G
J Affect Disord; 2018 Jun; 233():36-44. PubMed ID: 28918100
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation and clinical response to antidepressant medication in major depressive disorder: A review and recommendations.
Lisoway AJ; Zai CC; Tiwari AK; Kennedy JL
Neurosci Lett; 2018 Mar; 669():14-23. PubMed ID: 28063933
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.
Bousman CA; Arandjelovic K; Mancuso SG; Eyre HA; Dunlop BW
Pharmacogenomics; 2019 Jan; 20(1):37-47. PubMed ID: 30520364
[TBL] [Abstract][Full Text] [Related]
7. Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression.
Montano CB; Jackson WC; Vanacore D; Weisler R
Postgrad Med; 2023 Jun; 135(5):449-465. PubMed ID: 36912037
[TBL] [Abstract][Full Text] [Related]
8. Serotonin Transporter Gene Promoter Hypomethylation as a Predictor of Antidepressant Treatment Response in Major Depression: A Replication Study.
Schiele MA; Zwanzger P; Schwarte K; Arolt V; Baune BT; Domschke K
Int J Neuropsychopharmacol; 2021 Mar; 24(3):191-199. PubMed ID: 33125470
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Modifications of Major Depressive Disorder.
Saavedra K; Molina-Márquez AM; Saavedra N; Zambrano T; Salazar LA
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27527165
[TBL] [Abstract][Full Text] [Related]
10. DNA Methylation in Depression and Depressive-Like Phenotype: Biomarker or Target of Pharmacological Intervention?
Paoli C; Misztak P; Mazzini G; Musazzi L
Curr Neuropharmacol; 2022 Nov; 20(12):2267-2291. PubMed ID: 35105292
[TBL] [Abstract][Full Text] [Related]
11. The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review.
Webb LM; Phillips KE; Ho MC; Veldic M; Blacker CJ
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32012861
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic Decision Support Tools: A New Paradigm for Late-Life Depression?
Abbott R; Chang DD; Eyre HA; Bousman CA; Merrill DA; Lavretsky H
Am J Geriatr Psychiatry; 2018 Feb; 26(2):125-133. PubMed ID: 29429869
[TBL] [Abstract][Full Text] [Related]
13. Personalized medicine in major depressive disorder -- opportunities and pitfalls.
Miller DB; O'Callaghan JP
Metabolism; 2013 Jan; 62 Suppl 1(0 1):S34-9. PubMed ID: 23021040
[TBL] [Abstract][Full Text] [Related]
14. Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment.
Frieling H; Tadić A
Int Rev Psychiatry; 2013 Oct; 25(5):572-8. PubMed ID: 24151802
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of antidepressant response: A polygenic approach.
García-González J; Tansey KE; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Žagar T; Czerski PM; Jerman B; Buttenschøn HN; Schulze TG; Zobel A; Farmer A; Aitchison KJ; Craig I; McGuffin P; Giupponi M; Perroud N; Bondolfi G; Evans D; O'Donovan M; Peters TJ; Wendland JR; Lewis G; Kapur S; Perlis R; Arolt V; Domschke K; ; Breen G; Curtis C; Sang-Hyuk L; Kan C; Newhouse S; Patel H; Baune BT; Uher R; Lewis CM; Fabbri C
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Apr; 75():128-134. PubMed ID: 28159590
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic techniques in pharmacogenetics.
Heil SG
Methods Mol Biol; 2013; 1015():179-88. PubMed ID: 23824856
[TBL] [Abstract][Full Text] [Related]
17. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
18. Identifying genetic loci affecting antidepressant drug response in depression using drug-gene interaction models.
Noordam R; Avery CL; Visser LE; Stricker BH
Pharmacogenomics; 2016 Jun; 17(9):1029-40. PubMed ID: 27248517
[TBL] [Abstract][Full Text] [Related]
19. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life.
Chang DD; Eyreeuro HA; Abbott R; Coudreaut M; Baune BT; Shaman JA; Lavretsky H; Lenze EJ; Merrill DA; Singh AB; Mulsant BH; Reynolds CF; Müller DJ; Bousman C
Pharmacogenomics; 2018 Nov; 19(16):1269-1284. PubMed ID: 30422065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
